Ultra Market Research | United Kingdom Oxaliplatin Market
United Kingdom Oxaliplatin Market
Report ID : 976
Category : Therapeutic-Area,United-Kingdom(UK)
No Of Pages : 88
Published on: January 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United Kingdom Oxaliplatin Market Introduction Advanced colorectal cancer treatment involves the United Kingdom Oxaliplatin Market. Oxaliplatin is one of the platinum-based chemotherapy agents that find extensive use, especially in combination regimens such as FOLFOX. The drug interrupts the replication process of the DNA found in cancer cells and leads to apoptosis. In the UK, the market has steadily grown because of the rising prevalence of cancer as well as advancement in oncology. The market size was estimated to be around £200 million in 2023. The CAGR is expected to be 4.5% from 2024 to 2030. Recent trends include enhanced R&D for reducing side effects and exploring biosimilars to increase affordability.
Segmentation Treatment Regimen • Combination Therapy o FOLFOX (Oxaliplatin, 5-FU, Leucovorin) o CapeOx (Oxaliplatin, Capecitabine) o Others • Monotherapy o Maintenance Therapy o Advanced Cancer Treatment • Biosimilars o Generic Oxaliplatin o Region-Specific Biosimilars o Others
Patient Demographics • Age Group o Geriatric Patients o Adults o Others • Gender o Male o Female • Cancer Stages o Stage III o Stage IV o Others
List of Market Players 1. Sanofi (France) 2. Teva Pharmaceutical Industries (Israel) 3. Pfizer Inc. (United States) 4. Sandoz (Germany) 5. Fresenius Kabi (Germany) 6. Cipla Ltd. (India) 7. Accord Healthcare (United Kingdom) 8. Mylan N.V. (United States) 9. Dr. Reddy’s Laboratories (India) 10. Baxter International (United States) 11. Amneal Pharmaceuticals (United States) 12. Intas Pharmaceuticals (India) 13. Hikma Pharmaceuticals (United Kingdom) 14. Aspen Pharmacare (South Africa) 15. Sun Pharmaceutical Industries (India)
Drivers Increasing cases of colorectal cancer are driving the United Kingdom Oxaliplatin Market. It is one of the fourth most common cancers in the UK. Early detection of cancer and easier access to chemotherapy through the government also propels the market. Advancements in biosimilars and combination therapies also increase the availability and effectiveness of oxaliplatin. Improvements in drug delivery mechanisms, including nano-formulations, have enhanced its therapeutic profile further, leading to increased adoption in clinical settings.
Restraints Despite the growth potential, the market faces challenges in terms of high treatment costs, making it difficult for patients to afford. Side effects such as peripheral neuropathy from the use of oxaliplatin often cause the treatment to be discontinued. Additionally, alternative therapies and rigorous regulatory approvals for biosimilars limit market growth.
Opportunity Growing personalized medicine market opens significant doors for oxaliplatin formulations customized to individual genetic profiles. Expanding infrastructures of healthcare and nationwide cancer awareness campaigns in the UK will open doors for penetration into the market. In addition, joint ventures by pharmaceutical companies and research-based institutions aimed at discovering new therapeutic combinations are going to improve market prospects.
Trend Biosimilars are increasingly being adopted in the United Kingdom Oxaliplatin Market to decrease the treatment cost. Clinical trials based on artificial intelligence are speeding up the development and approval of drugs. Researchers are now targeting to decrease neurotoxicity associated with oxaliplatin and enhance the compliance of patients. "Increasing telemedicine usage for cancer consultation helps promote easier access of patients to oxaliplatin therapies.".
Key Target Audience • Oncology Specialists • Pharmaceutical Manufacturers • Research Institutions • Healthcare Providers • Government and Regulatory Bodies
Frequently Asked Questions (FAQ's)
The market was valued at approximately £200 million in 2023.
Increasing colorectal cancer cases and advancements in combination therapies are key drivers.
Sanofi, Pfizer Inc., and Accord Healthcare are among the top players.
High costs, adverse side effects, and stringent regulations challenge growth.
Growth in biosimilars and personalized medicine offer significant potential.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Treatment Types 3.2.2 By Patient Demographics 3.2.3 By Distribution Channels 3.2.4 By Therapeutic Applications 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
4. United Kingdom Oxaliplatin Market by Treatment Types 4.1 Introduction 4.2 Market Size and Growth Rate by Treatment Types (2024–2030) 4.2.1 Combination Therapy 4.2.1.1 FOLFOX Regimen 4.2.1.2 CapeOx Regimen 4.2.1.3 Other Combination Therapies 4.2.2 Monotherapy 4.2.2.1 Maintenance Treatment 4.2.2.2 Palliative Care 4.2.3 Biosimilars and Generics 4.2.3.1 UK-Specific Biosimilars 4.2.3.2 Generic Oxaliplatin
5. United Kingdom Oxaliplatin Market by Patient Demographics 5.1 Introduction 5.2 Market Size and Growth Rate by Patient Demographics (2024–2030) 5.2.1 By Age Group 5.2.1.1 Geriatric Patients 5.2.1.2 Adults (30–60 years) 5.2.1.3 Young Adults and Adolescents 5.2.2 By Gender 5.2.2.1 Male 5.2.2.2 Female
6. United Kingdom Oxaliplatin Market by Distribution Channels 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channels (2024–2030) 6.2.1 Hospital Pharmacies 6.2.1.1 Oncology Centers 6.2.1.2 General Hospitals 6.2.2 Retail Pharmacies 6.2.2.1 Independent Pharmacies 6.2.2.2 Chain Pharmacies 6.2.3 Online Pharmacies
7. United Kingdom Oxaliplatin Market by Therapeutic Applications 7.1 Introduction 7.2 Market Size and Growth Rate by Therapeutic Applications (2024–2030) 7.2.1 First-Line Treatment 7.2.1.1 Stage II and Stage III Cancer 7.2.1.2 Stage IV Cancer 7.2.2 Relapsed or Refractory Colorectal Cancer 7.2.2.1 Oxaliplatin-Based Combination Therapies 7.2.2.2 Experimental Therapeutic Combinations
10. Appendix 10.1 List of Tables • Table 1: United Kingdom Oxaliplatin Market Size by Treatment Types, 2024–2030 (USD Million) • Table 2: Market Size by Patient Demographics, 2024–2030 (USD Million) • Table 3: Market Size by Distribution Channels, 2024–2030 (USD Million) • Table 4: Market Size by Therapeutic Applications, 2024–2030 (USD Million) • Table 5: Drivers Influencing the United Kingdom Oxaliplatin Market Growth • Table 6: Key Restraints Affecting Market Dynamics • Table 7: Opportunities in the United Kingdom Oxaliplatin Market • Table 8: Competitive Landscape and Company Market Share (2024) • Table 9: Approved Oxaliplatin-Based Products in the United Kingdom • Table 10: Pipeline/Pre-Registration Products
10.2 List of Figures • Figure 1: United Kingdom Oxaliplatin Market Dynamics (Drivers, Restraints, Opportunities) • Figure 2: Market Segmentation by Treatment Types (2024–2030) • Figure 3: Market Segmentation by Patient Demographics (2024–2030) • Figure 4: Market Segmentation by Distribution Channels (2024–2030) • Figure 5: Market Segmentation by Therapeutic Applications (2024–2030) • Figure 6: Growth Rate of Combination Therapy Subsegment, 2024–2030 • Figure 7: Competitive Landscape: Market Position of Key Players (2024) • Figure 8: Regulatory and Pre-Registration Product Analysis • Figure 9: Distribution Channel Market Share in the United Kingdom (2024) • Figure 10: United Kingdom Oxaliplatin Market Forecast (2024–2030)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United Kingdom market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United Kingdom Oxaliplatin Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United Kingdom Oxaliplatin Market for the past year and forecasts for the next six years. United Kingdom Oxaliplatin Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United Kingdom Oxaliplatin Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United Kingdom Oxaliplatin Market from different application industries in different regions.
Segmentation Treatment Regimen • Combination Therapy o FOLFOX (Oxaliplatin, 5-FU, Leucovorin) o CapeOx (Oxaliplatin, Capecitabine) o Others • Monotherapy o Maintenance Therapy o Advanced Cancer Treatment • Biosimilars o Generic Oxaliplatin o Region-Specific Biosimilars o Others
Patient Demographics • Age Group o Geriatric Patients o Adults o Others • Gender o Male o Female • Cancer Stages o Stage III o Stage IV o Others
